Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 9/20 | 0.47 |
| ▸ | PPARG | P37231 | 7/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | PTPRB | P23467 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20054837 | 0.85 | EPHX2 (0.51) | EPHX2PPARGESR1ESR2CA1 | |
| SCHEMBL3870170 | 0.85 | ESR1 (0.61) | EPHX2PPARGESR1ESR2CA1 | |
| SCHEMBL19647120 | 0.85 | CXCR1 (0.50) | EPHX2PPARGESR1ESR2CA1 | |
| SCHEMBL13078733 | 0.85 | ESR1 (0.61) | EPHX2PPARGESR1ESR2CA1 | |
| SCHEMBL3662079 | 0.85 | ESR1 (0.61) | EPHX2PPARGESR1ESR2CA1 | |
| SCHEMBL28201178 | 0.83 | EPHX2 (0.64) | EPHX2PPARGPPARA | |
| SCHEMBL1887761 | 0.83 | HDAC1 (0.50) | EPHX2PPARGESR1ESR2CA1 | |
| SCHEMBL117431 | 0.83 | CYP1A2 (0.60) | EPHX2PPARGCYP1A2PPARA | |
| SCHEMBL4679627 | 0.81 | FOLH1 (0.48) | EPHX2PPARGCA1CA2PPARA | |
| SCHEMBL27224676 | 0.80 | EPHX2 (0.44) | EPHX2PPARGESR1ESR2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492345-B2 | Cyclic peptide antitumor agents | NORTHWESTERN UNIVERSITY (US) | 2013-07-23 | — | — | US | disclosed |
| US-20120122799-A1 | CYCLIC PEPTIDE ANTITUMOR AGENTS | NORTHWESTERN UNIVERSITY (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122799-A1 | CYCLIC PEPTIDE ANTITUMOR AGENTS | VIP, IAPP, NGLY1 | EPHX2 4804/4885PPARG 4421/4885ESR1 3324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.